Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74


Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.

Sugitani I, Onoda N, Ito KI, Suzuki S.

J Nippon Med Sch. 2018;85(1):18-27. doi: 10.1272/jnms.2018_85-3.


Improvement of treatment outcomes after implementation of comprehensive pharmaceutical care in breast cancer patients receiving everolimus and exemestane.

Todo M, Ueda S, Osaki S, Sugitani I, Takahashi T, Takahashi M, Makabe H, Saeki T, Itoh Y.

Pharmazie. 2018 Feb 1;73(2):110-114. doi: 10.1691/ph.2018.7837.


TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.

Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T, Osaki A, Saeki T, Horie-Inoue K, Inoue S.

Int J Mol Sci. 2017 Sep 8;18(9). pii: E1931. doi: 10.3390/ijms18091931.


Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.

Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K, Tsukada K.

Thyroid. 2017 Sep;27(9):1142-1148. doi: 10.1089/thy.2016.0621. Epub 2017 Jul 24.


Fibrotic focus: An important parameter for accurate prediction of a high level of tumor-associated macrophage infiltration in invasive ductal carcinoma of the breast.

Shimada H, Hasebe T, Sugiyama M, Shibasaki S, Sugitani I, Ueda S, Gotoh Y, Yasuda M, Arai E, Osaki A, Saeki T.

Pathol Int. 2017 Jul;67(7):331-341. doi: 10.1111/pin.12550. Epub 2017 Jun 7.


Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.

Sugitani I, Ueda S, Sakurai T, Shigekawa T, Hirokawa E, Shimada H, Takeuchi H, Matsuura K, Misumi M, Fujiuchi N, Takahashi T, Hasebe T, Osaki A, Saeki T.

Int J Clin Oncol. 2017 Oct;22(5):880-886. doi: 10.1007/s10147-017-1136-8. Epub 2017 May 25.


Thick tumor capsule is a valuable risk factor for distant metastasis in follicular thyroid carcinoma.

Shimbashi W, Sugitani I, Kawabata K, Mitani H, Toda K, Yamada K, Sato Y.

Auris Nasus Larynx. 2018 Feb;45(1):147-155. doi: 10.1016/j.anl.2017.05.002. Epub 2017 May 12.


Expression of MRP1 and ABCG2 is associated with adverse clinical outcomes of papillary thyroid carcinoma with a solid component.

Ohashi R, Kawahara K, Namimatsu S, Okamura R, Igarashi T, Sugitani I, Naito Z.

Hum Pathol. 2017 Sep;67:11-17. doi: 10.1016/j.humpath.2017.03.012. Epub 2017 Apr 11.


Timing of multikinase inhibitor initiation in differentiated thyroid cancer.

Brose MS, Smit J, Lin CC, Pitoia F, Fellous M, DeSanctis Y, Schlumberger M, Tori M, Sugitani I.

Endocr Relat Cancer. 2017 May;24(5):237-242. doi: 10.1530/ERC-17-0016. Epub 2017 Mar 7.


Fine needle aspiration cytology of the papillary thyroid carcinoma with a solid component: A cytological and clinical correlation.

Ohashi R, Murase Y, Matsubara M, Watarai Y, Igarashi T, Sugitani I, Naito Z.

Diagn Cytopathol. 2017 May;45(5):391-398. doi: 10.1002/dc.23679. Epub 2017 Feb 22.


Clinicopathological significance of a solid component in papillary thyroid carcinoma.

Ohashi R, Kawahara K, Namimatsu S, Igarashi T, Sakatani T, Sugitani I, Naito Z.

Histopathology. 2017 Apr;70(5):775-781. doi: 10.1111/his.13132. Epub 2017 Jan 18.


The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study.

Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, Ito K, Yoshida A, Suganuma N, Nakashima N, Suzuki S, Tsukahara K, Noguchi H, Koizumi M, Nemoto T, Hara H, Miyauchi A, Sugitani I.

Thyroid. 2016 Sep;26(9):1293-9. doi: 10.1089/thy.2016.0072.


Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review].

Ito Y, Suzuki S, Ito K, Imai T, Okamoto T, Kitano H, Sugitani I, Sugino K, Tsutsui H, Hara H, Yoshida A, Shimizu K.

Endocr J. 2016 Jul 30;63(7):597-602. doi: 10.1507/endocrj.EJ16-0064. Epub 2016 May 20. Review.


The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: A systematic review and meta-analysis.

Kwon J, Kim BH, Jung HW, Besic N, Sugitani I, Wu HG.

Eur J Cancer. 2016 May;59:34-45. doi: 10.1016/j.ejca.2016.02.015. Epub 2016 Mar 23. Review.


Histopathological analysis of anaplastic thyroid carcinoma cases with long-term survival: A report from the Anaplastic Thyroid Carcinoma Research Consortium of Japan.

Hirokawa M, Sugitani I, Kakudo K, Sakamoto A, Higashiyama T, Sugino K, Toda K, Ogasawara S, Yoshimoto S, Hasegawa Y, Imai T, Onoda N, Orita Y, Kammori M, Fujimori K, Yamada H.

Endocr J. 2016 May 31;63(5):441-7. doi: 10.1507/endocrj.EJ15-0705. Epub 2016 Feb 3.


Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time-Dependent Changes in Calcification and Vascularity During Active Surveillance.

Fukuoka O, Sugitani I, Ebina A, Toda K, Kawabata K, Yamada K.

World J Surg. 2016 Mar;40(3):529-37. doi: 10.1007/s00268-015-3349-1.


Ultrasonographic and non-enhanced CT features of acute transient thyroid swelling following fine-needle aspiration biopsy: report of four cases.

Yamada K, Toda K, Ebina A, Motoi N, Sugitani I.

J Med Ultrason (2001). 2015 Jul;42(3):417-25. doi: 10.1007/s10396-014-0600-6. Epub 2014 Dec 25.


Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2).

Onoda N, Sugitani I, Higashiyama T, Hara H, Ito K, Kammori M, Sugino K, Suzuki S, Toda K, Yoshida A, Miyauchi A.

BMC Cancer. 2015 Jun 20;15:475. doi: 10.1186/s12885-015-1490-8.


Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.

Shimada H, Ueda S, Saeki T, Shigekawa T, Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T, Matsuura K, Yamane T, Kuji I, Hasebe T, Osaki A.

Jpn J Clin Oncol. 2015 Jul;45(7):642-9. doi: 10.1093/jjco/hyv055. Epub 2015 May 19.


Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.

Shigekawa T, Osaki A, Sekine H, Sato N, Kanbayashi C, Sano H, Takeuchi H, Ueda S, Nakamiya N, Sugitani I, Sugiyama M, Shimada H, Hirokawa E, Takahashi T, Saeki T.

BMC Cancer. 2015 Apr 10;15:253. doi: 10.1186/s12885-015-1289-7.

Supplemental Content

Loading ...
Support Center